Sign Up

Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships
Flyout Menu
Main Menu

News

MICROB-PREDICT related activities at EASL Congress 2024

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Read more about the projectWednesday 5 June

When Where What
08:30-18:00 Poster area Poster WED-078: Systemic albumin administration improves the gut microbiome and intestinal permeability in animal models of cirrhosis and ACLF” (Alex Philipps)
08:30-18:00 Poster area Poster WED-069: Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of extrahepatic organ failure in acute-on-chronic liver failure (ACLF) (Alexandra Phillips)
08:30-18:00 Poster area Poster WED-111: Plasma proteomics uncovers progression markers of Acute-on-Chronic Liver Failure (Florian Rosenberger)
08:30-18:00 Poster area Poster WED-083: Multi-compartment metabolomics for stratifying cirrhotic patients with acute decompensation (Christophe Junot)
08:30-18:00 Poster area Poster TOP-073: Extensive characterization of new biomarkers associated with infection and outcome of decompensation of cirrhosis using high throughput metabolomics, lipidomics and cytokinomics (Cristina López-Vicario)
08:30-18:00 Poster area Poster WED-548: Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease (Maximilian Brol)
08:30-18:00 Poster area Poster WED-055: Effect of long-term treatment with Simvastatin and Rifaximin in mitochondrial and proinflammatory pathways in patients with decompensated cirrhosis. A single-cell RNA seq analysis in PBMCs (Adria Juanola)
08:30-18:00 Poster area Poster WED-545-YI: Restoration of mucosa-associated invariant T (MAIT) cell function and metabolism in cirrhosis with rifaximin-a (Thomas Tranah)
08:30-18:00 Poster area Poster WED-563: Phages targeting Enterococcus B bacteria associated with increased short-term mortality and proven bacterial infection in patients with decompensated liver cirrhosis and ACLF (Lore Van Espen)
14:00-14:45 Cirrhosis & Complications Track Hub MICROB-PREDICT Track-Hub Session

  • Linking Gut Microbiome Enterotypes and Dysbiosis to Liver Disease Severity and Prognosis (Marisa Isabell Keller)
  • Variation of the human microbiome across multiple body sites and temporal dynamics in different stages of decompensated cirrhosis (Wenyi Gu)
  • The linoleic acid-derived leukotoxin 9,10-DiHOME drives immunosuppression in patients with acute-on-chronic liver failure (Bryan Contreras)
  • Long-term albumin infusion reduces the mortality of cirrhosis and ACLF animal models by modulating the gut-liver axis and hepatic TLR4 signalling (Alex Philipps)
  • A spatiotemporal map of the hepatocyte proteome in alpha-1 antitrypsin deficiency by single-cell and visual proteomics (Florian Rosenberger)
19:30 Restaurant „Dry Milano“ ALB-TRIAL investigator dinner (invitation only)

Thursday 6 June

When Where What
08:30-18:00 Poster area Poster THU-053: Longitudinal salivary metagenomics in acute-on-chronic liver failure patients (Xavier Raffoux (Jouy-en-Josas, France))
08:30-18:00 Poster area Poster THU-056: Soluble PD-L1 levels as predictors of ACLF in decompensated cirrhosis: findings from two independent cohorts (Adrià Juanola)
08:30-18:00 Poster area Poster THU-055: Differential impact of proton pump inhibitors, statins, and non-selective beta-blockers on survival in different stages of chronic liver disease (Wenyi Gu)
08:30-18:00 Poster area Poster THU-080-YI: The predictive role of immunoglobulins indicative of gut barrier dysfunction in a prospective patient cohort with cirrhosis and acute decompensation (Dávid Tornai)
08:30-09:50

08:30-08:52

08:52-09:01

09:23-09:45

 Amber 3+4 Symposium (General Hepatology): The most challenging Expert Opinion articles published in Journal of Hepatology, a debate

Chair: Paolo Angeli

  • Talk: Towards a new definition of decompensated cirrhosis (Paolo Angeli, Jonel Trebicka)
  • Talk: Award to the three top Reviewers (Thomas Reiberger, Salvatore Piano)
  • Talk: From MAFLD to MASLD; where we are after one year (Maja Thiele)
12:30-14:00

12:30-12:35

12:35-12:45

12:45-13:15

13:15-13:30

13:30-14:00

 MiCo South – Level +2 – Room Amber 5 MICROB-PREDICT Investigator Meeting

  • Introduction (Aleksander Krag / Jonel Trebicka)
  • Summary of trial protocol (Nikolaj Torp)
  • Status on-site activation, screening and recruitment (Nikolaj Torp)
  • Data management (Peter Andersen)
  • Open action points & discussion (Nikolaj Torp)
16:15-17:00 Track Hub: Cirrhosis & Complications

 

 MICROB-PREDICT Poster Tour

Overview from the coordinator (Jonel Trebicka)

  • Poster THU-053 Longitudinal salivary metagenomics in acute-on-chronic liver failure patients (Xavier Raffoux)
  • Poster WED-083 Multi-compartment metabolomics for stratifying cirrhotic patients with acute decompensation (Christophe Junot)
  • Poster WED-111 Plasma proteomics uncovers progression markers of Acute-on-Chronic Liver Failure (Florian Rosenberger)
  • Poster THU-080-YI The predictive role of immunoglobulins indicative of gut barrier dysfunction in a prospective patient cohort with cirrhosis and acute decompensation (David Tornai)
  • Poster WED-078 Systemic albumin administration improves the gut microbiome and intestinal permeability in animal models of cirrhosis and ACLF (Alex Philipps)
  • Poster THU-055 Differential impact of proton pump inhibitors, statins, and non-selective beta-blockers on survival in different stages of chronic liver disease (Wenyi Gu)
17:00-18:30

17:15-17:30

18:00-18:15

 Space 1+2 Abstract session: Cirrhosis and its complications: Experimental

  • Talk: The linoleic acid-derived leukotoxin 9,10-DiHOME drives immunosuppression in patients with acute-on-chronic liver failure (Bryan Contreras)
  • Talk: Long-term albumin infusion reduces the mortality of cirrhosis and ACLF animal models by modulating the gut-liver axis and hepatic TLR4 signalling (Alex Philipps)

Friday 7 June

When Where What
08:30-18:00 Poster area Poster TOP-012: Validation of transient elastography and the enhanced liver fibrosis test as prognostic biomarkers across the spectrum of steatotic liver disease (Nikolaj Torp)
08:30-18:00 Poster area Poster FRI-041: Evaluating the influence of human albumin infusions on the MELD and MELD-Na scores in patients hospitalized with an acute decompensation of cirrhosis: an ATTIRE trial analysis (Nikolaj Torp)
08:30-18:00 Poster area Poster FRI-043: A multi-center randomized controlled study of primary prevention of esophageal variceal bleeding in cirrhotic patients treated with HVPG-guided therapy or standard heart rate-guided therapy: an interim analysis of the PORTHOS trial (Annelotte Broekhoven)
08:30-18:00 Poster area Poster FRI-064-YI: Impact of bacterial infections on kidney function and survival in patients with decompensated cirrhosis and acute kidney injury worldwide – analysis of the ICA-GLOBAL AKI study (Adrià Juanola)
08:30-18:00 Poster area Poster FRI-089: Infections and outcomes in patients hospitalized with an acute decompensation of cirrhosis: insights from the ATTIRE trial (Nikolaj Torp)
08:30-09:45 Brown 3 Abstract Session: Cirrhosis and its complications: Clinical

Co-Chairs: Minneke Coenraad, Joan Genescà
08:30-09:45

08:45-09:00

 Brown 1+2 Abstract session: Immune experimental and rare diseases – Basic

  • Talk: A spatiotemporal map of the hepatocyte proteome in alpha-1 antitrypsin deficiency by single-cell and visual proteomics (Florian Rosenberger)
12:30-14:00 MiCo South – Level +2 – Room Amber 6 MICROB-PREDICT Innovations meeting

  • Overview from the coordinator (Jonel Trebicka)
  • Available cohorts and datasets for collaboration (Wim Laleman / Wenyi Gu)
  • Samples and biological material (Minneke Coenraad / Robert Schierwagen)
  • Identified Biomarkers (Jonel Trebicka / Marisa Keller)
  • Guiding clinical decisions (Jonel Trebicka / Nikolaj Torp)
  • Discussion: What we have and what you need – Opportunities for collaboration
12:45-13:45

13:34-13:41

 Track Hub: Cirrhosis & Complications Poster tour: Cirrhosis and its Complications: Experimental and pathophysiology Chair: Maria Papp

  • WED-083: Multi-compartment metabolomics for stratifying cirrhotic patients with acute decompensation (Christophe Junot)
14:00-15:00

14:10-14:50

 Amber 7 Interactive Session: It’s all about the money: Toolkit to apply to European grants

Interactive sessions / One table per participant (Co-Speaker: Jonel Trebicka)
16:15-17:00

16:15-16:24

16:33-16:42

16:51-17:00

 Track Hub: Cirrhosis & Complications Poster tour: Cirrhosis and its Complications: ACLF and critical illness

  • THU-050 Urinary biomarkers of tubular and glomerular damage predict renal recovery in patients with hepatorenal syndrome-acute kidney injury (Salvatore Piano)
  • THU-056 Soluble PD-L1 levels as predictors of ACLF in decompensated cirrhosis: findings from two independent cohorts (Adrià Juanola)
  • THU-080-YI The predictive role of immunoglobulins indicative of gut barrier dysfunction in a prospective patient cohort with cirrhosis & acute decompensation (David Tornai)
17:15-18:30

17:15-17:30

17:30-17:45

18:00-18:15

 Brown 3 Abstract session: Gut microbiota and liver disease (Chairs: Jonel Trebicka; Minneke Coenraad)

  • Talk: Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling” (Lindsey Edwards)
  • Talk: Variation of the human microbiome across multiple body sites and temporal dynamics in different stages of decompensated cirrhosis (Wenyi Gu)
  • Talk: Linking gut microbiome enterotypes and dysbiosis to liver disease severity and prognosis (Marisa Keller)
17:45-18:00 Gold Room Abstract Session:

  • Talk: Steatotic liver disease classification is highly dynamic impacting eligibility for clinical trials and subclass-specific interventions (Mads Israelsen)
18:30-19:00 Amber 5

/ Non-industry meeting room 1

 MICROB-PREDICT / ELPA Patient event

Saturday 8 June

When Where What
08:30-09:45

08:32-08:44
08:44-08:56
09:08-09:20

 Brown 3 Future of hepatology: Decompensated cirrhosis: is it about portal hypertension or systemic inflammation

Co-Chairs: Virginia Hernández-Gea, Rajiv Jalan, Thomas Reiberger

  • Talk: Harmonizing definition of decompensation: Is it all about portal hypertension? (Thomas Reiberger)
  • Talk: Systemic inflammation across disease stages (pre/during/following decompensation) (Jonel Trebicka)
  • Talk: Emerging approaches to targeting systemic inflammation in cirrhosis (Rajiv Jalan)
  • Panel Discussion (chairs)
Share
Scroll to Top

Search EASL